taplucainium nebulizer (NOC-100) / Nocion Therap - LARVOL DELTA

Munich cCT Rule for Patients with Recreational Drug and Ethanol Poisoning. (PubMed, J Clin Med) - "The sensitivity and NPV for neurosurgical intervention were as follows: CCHR 50%/99.7%, NEXUS DI 100%/100%, NOC 100%/100%...The Munich cCT Rule for patients with recreational drug and ethanol poisoning may help rule out critical findings and is superior to the NEXUS DI and NOC. It also has a 100% sensitivity which the CCHR (25%) is lacking."

Journal • CNS Disorders • Hypotension • Musculoskeletal Diseases • Orthopedics

Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development (Businesswire) - "Nocion Therapeutics...today announced that it has raised $62 million in Series B funding. Nocion is developing first and potentially best in class, small molecule, permanently charged sodium channel blockers (CSCBs), called nocions, that selectively silence activated nociceptors for the treatment of serious conditions involving cough, itch, and pain. Proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study in Chronic Cough patients."

Financing • Chronic Cough

NTX-1175, A NOVEL CHARGED SODIUM CHANNEL BLOCKER, IS EFFECTIVE IN REDUCING STRESS AND POST-INFLAMMATORY INDUCED VISCERAL HYPERSENSITIVITY IN VIVO (DDW 2023) - "Colonic hypersensitivity was induced in rodent models of post-inflammation and chronic stress. NTX-1175, a novel charged sodium channel blocker that targets nociceptors, reversed colonic hypersensitivity in both models. These results suggest that NTX-1175 may relieve visceral hypersensitivity in disorders of gut brain interaction such as IBS."

Preclinical • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Pain

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175 (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Nocion Therapeutics

New P1 trial • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

NTX-1175 for Cough (LICS 2022) - "Sponsored by Nocion"

Cough • Respiratory Diseases